Detail page

Knowledge Web

Person

Torsten Haferlach

Arzt

Name	Torsten Haferlach
Place	Deutschland
Gender	männlich
Academic degree	Prof. Dr. med. Dr. phil.
Profession	Arzt (characteristic profession) Internist
Variant	T. Haferlach
Related	Leukämie (Thema)
Further information	MLL Münchner Leukämielabor GmbH, Facharzt für Innere Medizin, Hämatologe, Onkologe
Source	LCAuth
Record type	Person
GND-Identifier	111011159
Record ID	111011159
Involved in show all Hämatologische Erkrankungen : Atlas und diagnostisches Handbuch Normale Zellen des peripheren Blutes und der blutbildenden Organe Sachverzeichnis Störungen der weißen Zellreihen Titelei Weiterführende Literatur Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing Distinct characteristics of VEXAS-causative UBA1 M41 and recurrent functional non-M41 mutations Analysis of myeloid neoplasms with isolated trisomy 19 reveals a novel MDS subgroup characterized by the presence of ring sideroblasts, fibrosis and SRSF2 and/or ASXL1 mutations Sequential occurrence of BCR::ABL1-negative MPN and CML and vice versa: results from a real world cohort Two ways to complex karyotype in MDS—the role of del(5q) and TP53 Myelodysplastic neoplasms with ring sideroblasts without SF3B1 mutations in adults: enrichment of germline variants in congenital sideroblastic anemia genes Ruxolitinib mediated paradoxical JAK2 hyperphosphorylation is due to the protection of activation loop tyrosines from phosphatases Myeloid neoplasms with MYC-positive double minutes: towards recognition as a distinct entity Enhancer hijacking discovery in acute myeloid leukemia by pyjacker identifies MNX1 activation via deletion 7q Enhancing the informative value of bulk bone marrow RNA-seq by inferring the cell-type contributions Grauer Teil: Diagnostische Methoden: Labordiagnostik Ruxolitinib mediated paradoxical JAK2 hyperphosphorylation is due to the protection of activation loop tyrosines from phosphatases Taschenatlas Hämatologie : mikroskopische und klinische Diagnostik für die Praxis Taschenatlas Hämatologie : Mikroskopische und klinische Diagnostik für die Praxis Taschenatlas Hämatologie : Mikroskopische und klinische Diagnostik für die Praxis Genetic analysis of myeloid neoplasms with der(1;7)(q10;p10) HMX3 is a critical vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia Relevance of blast counts for genetic subclassification in MDS Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase A high proportion of germline variants in pediatric chronic myeloid leukemia Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes FBXL6 is a vulnerability in AML and unmasks proteolytic cleavage as a major experimental pitfall in myeloid cells Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study Parallel genomic analysis from paired bone marrow and peripheral blood samples of 200 cytopenic patients Analysis of 3760 hematologic malignancies reveals rare transcriptomic aberrations of driver genes Context-dependent role of trisomy 6 in myelodysplastic neoplasms and acute myeloid leukemia: a multi-omics analysis Genomic landscape of CCUS compared to MDS and its implications on risk prediction Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting Author Correction: Molecular patterns identify distinct subclasses of myeloid neoplasia Prognostic impact of CEBPA mutational subgroups in adult AML Genetic studies in clonal haematopoiesis, myelodysplastic neoplasms and acute myeloid leukaemia – a practical guide to WHO-HAEM5 Overview on WHO-HAEM5 and the diagnostic relevance of genetic alterations for the classification Collaborative effect of Csnk1a1 haploinsufficiency and mutant p53 in Myc induction can promote leukemic transformation Detection of a rare JAK2exon13InDel-mutation in chronic eosinophilic leukemia with bilateral cerebral infarctions and Löffler endocarditis TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia Molecular patterns identify distinct subclasses of myeloid neoplasia Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis Clonal evolution in chronic lymphocytic leukemia is associated with an unmutated IGHV status and frequently leads to a combination of loss of TP53 and TP53 mutation The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age Clinical application of whole transcriptome sequencing for the classification of patients with acute lymphoblastic leukemia Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q) Correction: complex landscape of alternative splicing in myeloid neoplasms

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Torsten Haferlach

Hämatologische Erkrankungen : Atlas und diagnostisches Handbuch

Normale Zellen des peripheren Blutes und der blutbildenden Organe

Sachverzeichnis

Störungen der weißen Zellreihen

Titelei

Weiterführende Literatur

Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing

Distinct characteristics of VEXAS-causative UBA1 M41 and recurrent functional non-M41 mutations

Analysis of myeloid neoplasms with isolated trisomy 19 reveals a novel MDS subgroup characterized by the presence of ring sideroblasts, fibrosis and SRSF2 and/or ASXL1 mutations

Sequential occurrence of BCR::ABL1-negative MPN and CML and vice versa: results from a real world cohort

Two ways to complex karyotype in MDS—the role of del(5q) and TP53

Myelodysplastic neoplasms with ring sideroblasts without SF3B1 mutations in adults: enrichment of germline variants in congenital sideroblastic anemia genes

Ruxolitinib mediated paradoxical JAK2 hyperphosphorylation is due to the protection of activation loop tyrosines from phosphatases

Myeloid neoplasms with MYC-positive double minutes: towards recognition as a distinct entity

Enhancer hijacking discovery in acute myeloid leukemia by pyjacker identifies MNX1 activation via deletion 7q

Enhancing the informative value of bulk bone marrow RNA-seq by inferring the cell-type contributions

Grauer Teil: Diagnostische Methoden: Labordiagnostik

Ruxolitinib mediated paradoxical JAK2 hyperphosphorylation is due to the protection of activation loop tyrosines from phosphatases

Taschenatlas Hämatologie : mikroskopische und klinische Diagnostik für die Praxis

Taschenatlas Hämatologie : Mikroskopische und klinische Diagnostik für die Praxis

Taschenatlas Hämatologie : Mikroskopische und klinische Diagnostik für die Praxis

Genetic analysis of myeloid neoplasms with der(1;7)(q10;p10)

HMX3 is a critical vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia

Relevance of blast counts for genetic subclassification in MDS

Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase

A high proportion of germline variants in pediatric chronic myeloid leukemia

Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes

FBXL6 is a vulnerability in AML and unmasks proteolytic cleavage as a major experimental pitfall in myeloid cells

Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation

Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study

Parallel genomic analysis from paired bone marrow and peripheral blood samples of 200 cytopenic patients

Analysis of 3760 hematologic malignancies reveals rare transcriptomic aberrations of driver genes

Context-dependent role of trisomy 6 in myelodysplastic neoplasms and acute myeloid leukemia: a multi-omics analysis

Genomic landscape of CCUS compared to MDS and its implications on risk prediction

Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting

Author Correction: Molecular patterns identify distinct subclasses of myeloid neoplasia

Prognostic impact of CEBPA mutational subgroups in adult AML

Genetic studies in clonal haematopoiesis, myelodysplastic neoplasms and acute myeloid leukaemia – a practical guide to WHO-HAEM5

Overview on WHO-HAEM5 and the diagnostic relevance of genetic alterations for the classification

Collaborative effect of Csnk1a1 haploinsufficiency and mutant p53 in Myc induction can promote leukemic transformation

Detection of a rare JAK2exon13InDel-mutation in chronic eosinophilic leukemia with bilateral cerebral infarctions and Löffler endocarditis

TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma

Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets

Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC

Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia

Molecular patterns identify distinct subclasses of myeloid neoplasia

Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age

Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q

SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase

SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis

Clonal evolution in chronic lymphocytic leukemia is associated with an unmutated IGHV status and frequently leads to a combination of loss of TP53 and TP53 mutation

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics

Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age

Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age

Clinical application of whole transcriptome sequencing for the classification of patients with acute lymphoblastic leukemia

Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)

Correction: complex landscape of alternative splicing in myeloid neoplasms